Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial

Overview of attention for article published in The Lancet HIV, April 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
Above-average Attention Score compared to outputs of the same age and source (52nd percentile)

Mentioned by

news: 1 news outlet
twitter: 21 X users

facebook: 3 Facebook pages

Citations

dimensions_citation: 74 Dimensions

Readers on

mendeley: 122 Mendeley

Summary News X Facebook Dimensions citations

So far, Altmetric has seen 25 X posts from 21 X users, with an upper bound of 162,295 followers.

New article: Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. https://t.co/MJg7Dg3ibe

02 Jun 2020

Reply Repost Favourite

Phase II of VRC01 broadly neutralising antibodies was not able to show significant therapeutic outcome, published in Lancet HIV https://t.co/c5HNfFYZ4i. Combination treatment being evaluated in two clinical studies: https://t.co/7beF2UKPPj

03 Jun 2019

Reply Repost Favourite

RT @TheLancetInfDis: New @TheLancetHIV: Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV…

18 Apr 2019

Reply Repost Favourite

RT @TheLancetInfDis: New @TheLancetHIV: Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV…

17 Apr 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 21 additional X posts.